Selective Androgen Receptor Degrader Ligands for CRPC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for castration-resistant prostate cancer (CRPC) are inadequate due to the re-activation of the androgen receptor (AR) through alternate mechanisms, such as AR splice variants and mutations, which are not effectively inhibited by existing AR antagonists, leading to treatment resistance and disease progression.
Innovation Solution
Development of novel selective androgen receptor degrader (SARD) compounds that bind to the N-terminal domain (NTD) and/or an alternate binding and degradation domain (BDD) of the AR, degrading both full-length and splice variant ARs, thereby inhibiting their activity and providing a unique mechanism to target treatment-resistant CRPC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AR antagonists are used to treat prostate cancer, then initial treatment response is achieved, but treatment resistance develops due to AR re-activation through splice variants and mutations
Solution Approach 1:
Instead of blocking AR signaling (the conventional approach), the patent inverts the mechanism by degrading the AR protein itself through proteasomal pathways. This fundamental inversion from signal blockade to protein destruction overcomes resistance caused by splice variants and mutations that evade conventional antagonists.
Solution Approach 2:
The patent changes the molecular parameter of AR interaction from reversible binding (antagonists) to irreversible degradation. By designing compounds that trigger ubiquitin-mediated proteasomal degradation, the treatment transitions from temporary signal blockade to permanent protein removal, eliminating resistance mechanisms.
2Reliability
If AR splice variants and mutations are targeted, then treatment resistance is overcome, but existing AR antagonists fail to bind to these variants
Solution Approach 1:
The patent extracts the ligand-binding domain dependency from AR targeting. By designing degraders that work through alternative domains (such as the N-terminal domain) rather than the ligand-binding domain, the treatment becomes effective against splice variants that lack or alter the LBD, while conventional antagonists fail.
Solution Approach 2:
The patent creates a universal degrader mechanism that functions across multiple AR forms (wild-type, splice variants, mutants) through a single degradation pathway. This multi-functional approach allows one compound class to target diverse AR configurations that would require different mechanisms otherwise.
3Reliability
If new SARD compounds are developed to degrade AR, then treatment outcomes improve, but drug development complexity increases
Solution Approach 1:
The patent introduces the ubiquitin-proteasome system as an intermediary mechanism. Rather than directly eliminating AR, the degraders recruit cellular degradation machinery (ubiquitin ligases and proteasomes) to destroy the target protein. This intermediary approach simplifies drug design by leveraging existing cellular pathways.
Solution Approach 2:
The patent employs self-service by utilizing the cell's own proteasomal degradation machinery to eliminate AR. The degraders act as molecular switches that activate the cell's inherent protein quality control system against the pathological AR, rather than requiring externally engineered degradation mechanisms.
Data Source
AI summary
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.